WEBINAR
Using Data to Drive Launch Acceleration in MedTech & Life Sciences
In the fast-growing MedTech and diagnostic arena, time-to-market is key to meeting patients’ diagnostic and treatment needs, while also serving customer demand effectively and efficiently. With the heightened complexity of care delivery, stakeholders and partnerships, manufacturing processes and supply chains, adequate planning, and synchronization of multiple workstreams are paramount.
Listen to experts from EPAM, Invitae and Planisware in this insightful, on-demand panel conversation on the importance of acquiring and accessing the right data at the right time in the MedTech and life sciences industries. This discussion includes real lessons learned from practitioners on planning, accelerating time to launch, curating the proper data assets and utilizing resource tracking to “plan the work and work the plan” with agility.
Watch the webinar to learn:
- Typical launch risks, trends and critical success factors
- Prevention and mitigation strategies across functional departments to achieve target launch plans and forecasts
- How to avoid resource bottlenecks for better delivery
- Examples of best-in-class launch architecture, including infrastructure, capabilities, data asset management, insights and other tools needed for a timely launch
Complete the form to watch the full webinar now!
Meet the Panelists
Christine Horan
Senior Director, Innovation Consulting, EPAM
Christine has over 20 years of experience in product development and, in addition to leading EPAM's Physical Technology team, leads multidisciplinary programs for clients in MedTech, life sciences, packaging and consumer products.
Dave Penndorf
VP of Sales, Life Sciences, Planisware
Dave has worked with life sciences organizations for his entire 15+ year career at Planisware, from enterprise-wide applications at the largest companies in the world to 10-user deployments at smaller biotechs.
Nasha Fitter
Global Head, Data Platform, Invitae
Nasha leads the Data Platform business unit at Invitae, where she works closely with patients, advocacy groups and biopharma companies to build natural history studies and utilize real world evidence to accelerate treatments for rare diseases.